The Interplay of Apolipoprotein B and Systemic Inflammation in Atherosclerotic Cardiovascular Disease: Causality, Mechanisms, and Clinical Paradigms

Atherosclerotic cardiovascular diseaseCardiovascular disease is the umbrella term for problems with the heart and blood vessels, including heart attacks, strokes, and blocked leg arteries. (ASCVD) remains the leading cause of morbidity and mortality worldwide. For decades, the field debated the fundamental pathophysiological nature of atherogenesisAtherogenesis is the step-by-step process of a plaque forming.. Early formulations of the lipid hypothesis viewed atherosclerosisAtherosclerosis is the disease behind most heart attacks and many strokes. Cholesterol particles get stuck in the wall of an artery, the body sends immune cells to clean up, and over years that mess hardens into plaque. largely as a disease of cholesterolCholesterol is a waxy substance your body needs. It goes into cell walls, hormones, vitamin D, and the bile that digests your food. You would die without it. accumulation within the arterial wall, whereas subsequent pathological observations highlighting macrophagesA macrophage is a large immune cell that swallows debris and invaders. The name literally means "big eater.", T cells, and other inflammatory cells within plaquesPlaque is the buildup of cholesterol, immune cells, scar tissue, and calcium inside an artery wall. fostered the competing view that ASCVD was primarily a chronic inflammatory disorder. Advances in vascular biology, geneticsGenetics is the study of what you inherit from your parents., and clinical trialA clinical trial is a study where researchers give one group a treatment and another group a placebo or standard care, then compare what happens. science now show that these are not mutually exclusive explanations but interlocking components of the same disease process.[1,12,13,22]

Current scientific and clinical consensus characterizes atherosclerosis as a lipid-driven inflammatory disease. Within this model, apolipoproteinAn apolipoprotein is a protein attached to a fat-carrying particle in your blood. Fat and water don't mix, so these proteins act like a wrapper that lets fat travel safely through the bloodstream. B (ApoBApoB is a protein that sits on the outside of every cholesterol particle that can get stuck in your artery wall and cause plaque. Each of those particles carries exactly one ApoB.)-containing lipoproteinsA lipoprotein is a tiny package that carries fat and cholesterol through your bloodstream. Since fat won't dissolve in water, it needs a protein wrapper to travel. provide the indispensable initiating insult, while systemic and local inflammationInflammation is your immune system's response to injury or something it treats as an invader. It brings swelling, heat, and cleanup cells. amplifies plaque growth, vulnerability, and rupture risk. Put differently, the lesionIn cardiology, a lesion refers to a discrete area of atherosclerotic plaque narrowing a coronary artery, typically described by the percentage of luminal obstruction it causes. The article describes four residual lesions too small in vessel diameter to accept a stent after the most critical one was treated. begins with retention of atherogenic ApoB particles and becomes dangerous through a maladaptive immune response to retained and modified lipid.[2-5,12,13,21,22]

This review examines the relationship between ApoB, inflammation, and ASCVD progression. By tracing the causal sequence of plaque initiation, reviewing the molecular pathway from lipid retention to cytokine activation, and integrating human genetics with major cardiovascular outcomes trials, it develops a unified model of atherogenesis. The central thesis is that ApoB burden determines whether disease begins, while inflammatory biology strongly influences the pace of progression and the likelihood of myocardial infarctionSee Heart Attack for the full entry., strokeA stroke happens when blood flow to part of the brain stops, either from a blockage or from bleeding., or cardiovascular death.[2-5,6-9,12-18,21]

The Causal Sequence: The Response-to-Retention Hypothesis

To understand the relationship between ApoB and inflammation, the temporality of the initial atherogenic event must be established. The key mechanistic question is whether elevated ApoB-containing lipoproteins initiate atherosclerosis before localized inflammation develops, or whether inflammation first primes the arterial wall and subsequently permits lipid deposition. Current evidence strongly favors a sequence in which disease begins with arterial retention of ApoB particles, with inflammation arising as a biological response to those retained particles and then feeding forward to worsen disease.[2-5]

Histopathological and experimental evidence supports the response-to-retention hypothesisThe response-to-retention hypothesis is the leading mechanistic account of early atherosclerosis, holding that the initiating event is the binding and trapping of apoB-containing lipoprotein particles to proteoglycans in the arterial intima, before inflammation or foam cell formation occurs. of early atherogenesis. In the classic formulation by Williams and Tabas, the influx and trapping of cholesterol-rich ApoB particles within the arterial intimaThe intima is the innermost layer of an artery wall, sitting just beneath the smooth lining. are the necessary first steps in lesion formation. The later Circulation update on subendothelial lipoprotein retention states directly that the initiating process in atherogenesis is retention of ApoB-containing lipoproteins beneath the endotheliumThe endothelium is the ultra-thin, slippery lining on the inside of every blood vessel. It is only one cell thick., which then triggers the macrophage- and T-cell-dominated inflammatory response that drives lesion development.[2,3]

This model remains compelling because it integrates arterial biology, extracellular matrixThe extracellular matrix is the scaffolding of collagen and other fibers that holds tissue together and gives an artery wall its strength. binding, and clinical observation. The ApoB particle is not merely a passive lipid carrier. ApoB-containing particlesLipoproteins—including LDL, IDL, VLDL, and their remnants—that each carry one molecule of apolipoprotein B on their surface; particle number (rather than cholesterol mass alone) is a key driver of atherosclerosis because each particle can be retained in the arterial wall. bind arterial wall proteoglycans, especially in vascular regions predisposed to lesion formation. Once trapped, they are exposed to oxidative, enzymatic, and aggregative modification, which converts them into potent inflammatory stimuli. Thus, the earliest event is not generalized inflammation or nonspecific endothelial injury, but focal retention of atherogenic lipoproteins in a susceptible arterial microenvironment.[2-5]

Refuting the “Inflammation-First” Paradigm

Alternative models, most notably the response-to-injury hypothesis, proposed that endothelial injury or pre-existing inflammation must precede lipid deposition. This view gained traction because inflammatory cells are abundant in established plaques and because systemic inflammatory conditions accelerate ASCVD. Yet inflammatory acceleration does not prove inflammatory initiation. The decisive question is whether inflammation, in the absence of sufficient ApoB exposure, can generate a typical cholesterol-rich atheromatous lesion. The balance of evidence suggests that it cannot.[1-3,12,21,22]

Experimental and pathological data indicate that endothelial dysfunctionEndothelial dysfunction is when that thin lining stops doing its job well. Vessels don't widen properly, and the barrier gets leakier., altered shear stress, and inflammatory activation create a permissive environment for lesion formation, but ApoB burden determines whether lesions actually form and how extensively they progress. Disturbed flow helps explain lesion localization; retained ApoB-containing lipoproteins explain lesion initiation and expansion.[2-5,12,22]

Systemic inflammation nevertheless acts as a powerful disease amplifier. Chronic inflammatory states increase endothelial activation, alter vascular signaling, and accelerate plaque progression. However, in a lipid-poor environment they do not generate the classic cholesterol-laden lesion that defines atherosclerosis. This distinction is clinically important because it explains why anti-inflammatory therapy does not eliminate the need for intensive ApoB lowering.[1,12,13,21,22]

Apolipoprotein B: The Initiating Variable

ApoB exists in 2 major atherogenic isoforms: ApoB48 and ApoB100. ApoB48 is synthesized in the intestine and is present in chylomicronsA chylomicron is a very large particle that carries fat from a meal out of your intestines and into your bloodstream. and their remnants. ApoB100 is synthesized in the liver and is present in very-low-density lipoproteins, intermediate-density lipoproteins, low-density lipoproteins, and lipoprotein(a)Lipoprotein(a), written Lp(a) and said "L-P-little-a," is an LDL-like particle with an extra sticky protein attached. [Lp(a)]. Because each atherogenic particleAtherogenic particles are the ApoB-containing lipoproteins—including LDL, IDL, VLDL, and lipoprotein(a)—that can enter and be retained in the artery wall to initiate and sustain plaque growth; the article uses the term to describe what must be lowered substantially and sustainably to achieve plaque regression. contains exactly 1 ApoB molecule, plasma ApoB concentration reflects the total number of circulating atherogenic particles. This gives ApoB important conceptual and clinical advantages over LDL-C, which reflects cholesterol mass rather than particle number.[4,15,23,25,28]

The clinical importance of ApoB lies in the fact that atherosclerosis is driven by the number of particles capable of entering and being retained in the arterial wall, not simply the amount of cholesterol they carry. Cholesterol content per particle varies considerably, especially in insulin resistanceInsulin resistance is when your cells stop responding well to insulin, so your pancreas has to pump out more and more to do the same job., metabolic syndromeMetabolic syndrome is a cluster of five problems that tend to travel together: a large waist, high triglycerides, low HDL, high blood pressure, and high blood sugar. Having three or more counts., type 2 diabetesDiabetes is a condition where blood sugar stays too high, either because the body makes too little insulin or because it stops responding to the insulin it makes., and hypertriglyceridemia. In such states, LDL-C may underestimate the true burden of atherogenic particles, whereas ApoB captures that burden more directly.[4,23,25,26,28]

Entry of these particles into the arterial wall is driven by the concentration gradient from plasma into the intima. Once inside the subendothelial spaceThe subendothelial space is the narrow gap just beneath the artery's inner lining, between that single layer of cells and the muscle beneath., structural domains on ApoB facilitate retention by arterial proteoglycans. Retention prolongs particle residence time and creates the substrate for oxidation, aggregation, and immune activation. Without retention, the downstream inflammatory cascade does not develop in its canonical form.[2-5]

Lp(a) deserves special mention within the ApoB family because it combines an LDL-like ApoB-containing particle with apolipoprotein(a), and it appears to contribute both proatherogenic and proinflammatory effects. Genetic and clinical evidence now support Lp(a) as a causal ASCVD risk factorA risk factor is something that raises your chance of developing a disease — high cholesterol particles, high blood pressure, smoking, diabetes, family history..[15]

Mechanistic Pathways: From Arterial Retention to Systemic Inflammation

Following subendothelial retentionSubendothelial retention is the process by which ApoB-containing lipoprotein particles that have crossed the endothelial barrier become electrostatically bound to proteoglycans in the arterial intima and are unable to diffuse back into the bloodstream; it is considered the non-redundant first step in atherosclerosis under the response-to-retention framework. of ApoB-containing particles, a coordinated series of biological events transforms focal lipid accumulation into an inflammatory lesion. This pathway links hyperlipidemia to innate immune activation and explains how a clinically silent fatty streakA fatty streak is the earliest visible stage of atherosclerosis — a flat yellow smear of cholesterol-filled immune cells just under the artery lining. can evolve into a dangerous plaque.[2,5,10-14,21,22]

Lipoprotein modification

Once retained in the intimal extracellular matrix, ApoB-containing lipoproteins are exposed to oxidative and enzymatic modification. These processes generate oxidized LDLOxidized LDL is an LDL particle that has been chemically damaged after getting stuck in an artery wall., oxidized phospholipids, and aggregated particles with biological properties distinct from native lipoproteins. Such modified particles act as danger-associated signals within the vessel wall and alter endothelial and myeloid-cell behavior.[2,5,10-14]

These modified lipids are not passive cargo. They become inflammatory ligands that engage vascular and immune cells and sustain lesion evolution. Lp(a), because of its oxidized phospholipid burden, may function as an especially potent inflammatory vehicle after retention.[5,13,15]

Endothelial dysfunction and monocyte recruitment

Modified lipids interact with pattern-recognition pathways and activate inflammatory transcriptional programs in endothelial cellsThe thin layer of cells lining the inner surface of all blood vessels; they regulate vascular tone, prevent clotting, and control the passage of substances into the artery wall — and their dysfunction is an early, critical step in atherosclerosis. and macrophages. This suppresses atheroprotective endothelial signaling and promotes expression of leukocyte adhesionThe process by which white blood cells attach to the endothelial surface of blood vessels, a key early step in atherogenesis; nitric oxide and an intact glycocalyx normally suppress this adhesion. molecules and chemokines, marking the transition from silent lipid retention to active vascular inflammation.[12-14,21,22]

The result is recruitment of circulating monocytes and T lymphocytes into the subendothelial space. Monocytes adhere, migrate across the activated endothelium, and enter a lipid-rich microenvironment that favors differentiation into macrophages. This is the pivotal handoff from a biochemical lesion driven by lipoprotein retention to a cellular lesion dominated by immune effectors.[12-14,21,22]

Macrophage differentiation, foam cell formation, and crystal genesis

Within the intima, monocytes differentiate into macrophages and internalize modified lipoproteins through scavenger receptors. Because these uptake pathways are not adequately downregulated by intracellular cholesterol loading, macrophages continue to engulf lipid and become foam cellsA foam cell is an immune cell that has eaten so much trapped cholesterol that it swells up and looks foamy under a microscope., the hallmark of the early fatty streak.[10-14]

As lipid uptake outpaces cholesterol efflux, intracellular free cholesterol accumulates and can precipitate into cholesterol crystalsWhen cholesterol accumulates past what a plaque can hold in solution, it crystallizes into sharp needle-like structures.. These crystals are now recognized not as inert debris, but as inflammatory triggers that activate innate immune pathways central to plaque progression.[10,11,14]

The NLRP3 Inflammasome and Pyroptosis

The intracellular formation and phagocytosis of cholesterol crystals represent a key mechanistic link between retained lipid and innate immune activation. When macrophages attempt to process cholesterol crystals, lysosomal disruption and associated cellular stress activate the NLRP3 inflammasomeThe NLRP3 inflammasome is an intracellular protein complex in immune cells that, when activated by cholesterol crystals, oxidized lipids, or other danger signals within an atherosclerotic plaque, triggers the release of the inflammatory cytokines interleukin-1β and interleukin-6, accelerating plaque growth and instability., a multiprotein danger-sensing complex implicated in atherogenesis.[10,11,14]

Once assembled, NLRP3NLRP3 is an alarm system inside immune cells. When it detects something it treats as a threat, it triggers a burst of inflammatory signaling. activates caspase-1, which cleaves pro-IL-1β and pro-IL-18 into their mature forms and promotes inflammatory cell death pathways. This leads to release of cytokines, proteases, and lipid contents into the extracellular space, contributing to necrotic coreThe necrotic core is the dead, mushy center of an advanced plaque, built from immune cells that ate trapped cholesterol and then died in place. expansion and plaque destabilization. This is the point at which chronic lipid-storage lesions become actively destabilizing inflammatory lesions.[10,11,14]

This inflammasome-centered model is therapeutically important because it links retained lipid to IL-1β production and provides a mechanistic rationale for interventions such as canakinumabCanakinumab is a monoclonal antibody that targets interleukin-1β (IL-1β), a key inflammatory signaling protein; it was the active drug in the CANTOS trial, where it reduced cardiovascular events without affecting LDL cholesterol. and colchicineColchicine is an old, cheap anti-inflammatory drug, used for centuries in gout, now repurposed for heart disease..[6,10,11,14,29-32]

The Hepatic Synthesis of C-Reactive Protein

IL-1β release within the plaque amplifies inflammation both locally and systemically. IL-1β stimulates production of interleukin-6 (IL-6)A signaling protein produced in response to IL-1β during plaque inflammation that travels to the liver and stimulates CRP production; elevated circulating IL-6 therefore reflects active vascular inflammation. and other downstream mediators, and IL-6Interleukin-6, or IL-6, is a signaling molecule the immune system uses to spread an inflammatory message through the body. in turn induces hepatic synthesis of C-reactive proteinC-reactive protein, or CRP, is a substance your liver makes when there is inflammation somewhere in your body. A sensitive version of the test, hs-CRP, is used to estimate heart risk.. Elevated hs-CRP is therefore best understood as a systemic marker of inflammatory signaling arising, at least in part, from inflamed atherosclerotic lesions.[6,12,14,17,18,21,29]

Because CRP sits downstream of the IL-1β/IL-6 axis, it is clinically valuable as a biomarkerA biomarker is something measurable in the body that tells you about health or disease — a lab value, a scan result, a blood pressure reading. of inflammatory activity but may not itself be the causal driver of disease.[17,18,21]

The Role of CRP: Biomarker Versus Causal Mediator

Given the strong epidemiologic association between elevated hs-CRP and incident ASCVD, investigators asked whether CRP merely reflects vascular inflammation or directly contributes to atherogenesis. If CRP were causal, CRP itself would be an attractive therapeutic target. If it were only a marker, targeting CRP without affecting upstream pathways would be unlikely to reduce events.[17,18,21]

Evidence from Mendelian randomization

Mendelian randomizationMendelian randomization is a clever research method that uses the genes people were born with as a natural experiment. has been central to resolving this issue. Genetic studies of lifelong differences in CRP have generally shown null or near-null associations with coronary disease, whereas Mendelian randomizationRandomization is the process of assigning trial participants to treatment or control groups by chance, ensuring that known and unknown confounding factors are evenly distributed; when randomization fails—as auditors found occurred in PREDIMED—the groups may differ in ways that distort the apparent treatment effect. analyses of IL-6 signaling support pathway causality. This pattern strongly suggests that CRP is a downstream biomarker rather than the primary causal mediator.[17,18]

The IL6R Mendelian randomisation analysis is especially informative. Genetic downregulation of IL-6 receptor signaling is associated with lower inflammatory activity, lower downstream CRP, and lower coronary risk, supporting IL-6 pathway causality. This interpretation aligns with later clinical trial data showing benefit from IL-1β inhibition and with the broader view that upstream inflammatory circuitry, not CRP itself, is the relevant therapeutic target.[6,17,18,21]

Evidence from animal models regarding direct CRP effects has been mixed, especially compared with the more consistent genetic and clinical data implicating IL-1β and IL-6. On balance, CRP is best regarded as a high-value clinical biomarker rather than a central therapeutic target.[17,18,21]

Interaction Between ApoB and Inflammation: Landmark Clinical Evidence

Recognition that atherosclerosis depends on both ApoB accumulation and inflammatory amplification led to the modern concept of dual residual riskResidual risk is the risk that remains after you have done the obvious things — cholesterol treated, blood pressure controlled, not smoking. pathways. Some patients remain at high risk because their atherogenic particle burdenParticle burden refers to the total number of atherogenic lipoprotein particles circulating in the plasma, best measured by ApoB; it is distinguished from cholesterol mass because it is the physical count of particles — not the amount of cholesterol they carry — that determines how frequently lipoproteins infiltrate and become entrapped in the arterial wall. remains inadequately controlled. Others achieve major lipid loweringLipid lowering means reducing the harmful, ApoB-carrying particles in your blood — through food, medication, or both. but retain substantial inflammatory risk, reflected by elevated hs-CRP or persistent cytokine activation. Landmark trials such as JUPITERJUPITER tested a statin in people whose cholesterol was normal but whose CRP was elevated, suggesting hidden inflammation., CANTOSCANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) was a large randomized trial that tested canakinumab, a drug blocking the inflammatory signal IL-1β, against placebo; at its prespecified 150 mg dose it reduced major cardiovascular events by roughly 15% without lowering LDL cholesterol, providing direct human evidence that inflammation drives heart attacks through a pathway indepen…, and FOURIERFOURIER tested evolocumab, a PCSK9 inhibitor, in patients who already had cardiovascular disease and were on statins. illustrate these complementary pathways.[6-9,29,33]

JUPITER: inflammation in primary prevention

JUPITER enrolled apparently healthy individuals with LDL-C below 130 mg/dL and hs-CRP of at least 2.0 mg/L, thereby selecting a population with modest traditional lipid levels but increased inflammatory risk. RosuvastatinRosuvastatin, sold as Crestor, is the most potent statin available and stays largely in the liver rather than spreading through the body. reduced both LDL-C and hs-CRP and significantly lowered major cardiovascular events. The trial showed that clinically meaningful cardiovascular risk can exist despite “normal” LDL-C when inflammatory burden is elevated, and that a therapy with both lipid-lowering and anti-inflammatory effects can substantially reduce risk.[7]

CANTOS: isolating the inflammatory hypothesis

CANTOS directly tested whether inflammation reduction independent of lipid lowering improves outcomes. In patients with prior myocardial infarction and persistent hs-CRP elevation despite standard therapy, canakinumab substantially reduced IL-6 and hs-CRP without lowering LDL-C, HDL-C, or ApoB, and reduced recurrent cardiovascular events. Secondary analyses suggested greater benefit in those achieving deeper hs-CRP reduction. CANTOS therefore provided proof of principle that targeted anti-inflammatory therapy can reduce ASCVD events even when lipid levels remain unchanged.[6,29]

FOURIER: persistent inflammatory risk despite ultra-low lipid levels

FOURIER tested intensive lipid lowering with evolocumabEvolocumab is an injectable cholesterol medicine in the PCSK9 inhibitor family, usually given every two to four weeks. in patients with established ASCVD. Evolocumab reduced LDL-C dramatically, while hs-CRP remained essentially unchanged. The trial confirmed benefit from deeper lipid lowering, but subsequent analyses demonstrated that hs-CRP and LDL-C remained independent predictorsA variable that statistically forecasts an outcome—such as mortality—even after accounting for other known risk factors like age, BMI, and cholesterol through multivariable analysis. of outcomes. Even at very low LDL-C levels, higher hs-CRP identified higher residual risk. FOURIER thus showed that residual inflammatory riskResidual inflammatory risk refers to the persistent elevation of cardiovascular event rates in patients who have already achieved guideline-recommended LDL-C targets but continue to have elevated inflammatory markers such as hsCRP; it represents a second, parallel pathway of atherogenesis that lipid-lowering alone does not address. persists even when lipid risk is driven to very low levels.[8,9,33]

Together, these trials validate a dual-axis model. JUPITER highlighted inflammatory risk in primary preventionPrimary prevention is treating someone who has never had a heart attack or stroke, to keep the first one from happening., CANTOS showed that selective anti-inflammatory therapy reduces events without lipid lowering, and FOURIER showed that intense lipid lowering leaves a measurable pool of residual inflammatory risk. The implication is not to choose between lipid and inflammation, but to treat both.[6-9,29,33]

Epidemiological Synergy: Insights From UK Biobank and Contemporary Cohorts

Large population analyses complement trial data by showing how ApoB and inflammatory risk interact across broad risk distributions. Contemporary cohort studies and UK Biobank-based analyses indicate that ApoB burden and inflammatory markers often provide complementary information, with the highest event rates often observed when both are elevated. Particularly important are discordanceSee ApoB Discordance for the full entry. analyses showing that ApoB often predicts risk better than LDL-C when the 2 measures disagree.[4,23,25,28]

In metabolic syndrome and hypertriglyceridemia, LDL-C may appear deceptively low because each particle carries less cholesterol, whereas ApoB still reflects the true number of atherogenic particles. Recent cohort work also suggests that ApoB-based approaches can improve risk discrimination relative to cholesterol-based metrics in discordant states.[4,23,25,26,28]

These epidemiologic observations reinforce the mechanistic framework. Elevated ApoB indicates increased opportunity for arterial entry and retention, whereas elevated hs-CRP signals active inflammatory amplification. When both are present, risk rises materially. That does not place CRP on the same causal level as ApoB, but it does support measuring both to refine clinical risk assessment.[4,17,18,23,25,28]

Clinical Implications and 2025 Guideline Perspectives

Modern lipidology increasingly recognizes that because cholesterol mass per LDLLDL, or low-density lipoprotein, is the main particle that carries cholesterol through your blood — and the main one that gets stuck in artery walls. particle varies, reliance on total cholesterolTotal cholesterol adds together the cholesterol in all your particles, harmful and helpful alike. or calculated LDL-C alone can misclassify risk. ApoB directly inventories the circulating atherogenic particles capable of entering the arterial wall. The 2024 Circulation review on ApoB argues for broader clinical use of ApoB because of its stronger biologic alignment with ASCVD causality and its utility in discordant states.[4,23,25,28]

This shift is reflected in contemporary guidance. The 2025 AACE dyslipidemiaDyslipidemia is the medical word for an unhealthy pattern of fats in the blood. It can mean high LDL, high triglycerides, low HDL, or some combination. guideline emphasizes modern risk-based pharmacologic management, while the 2025 focused ESC/EAS update supports earlier and broader use of combination therapy, including statinsA statin slows the enzyme your liver uses to make cholesterol. Your liver responds by pulling more cholesterol out of your blood, which is where the real benefit comes from., ezetimibeEzetimibe is a pill that blocks your intestines from absorbing cholesterol., bempedoic acidBempedoic acid is a cholesterol-lowering pill that works in the liver, at a point just before where statins act., and PCSK9PCSK9 is a protein made by your liver that destroys the docking ports your liver uses to pull cholesterol out of your blood. inhibition, to reduce atherogenic burden. Although society-specific thresholds differ, the overall direction is consistent: ApoB is gaining prominence as an actionable marker, especially in high-risk and discordant patients.[19,20]

Inflammation has likewise moved from an academic concept to a clinically actionable one. The 2025 ACC scientific statement emphasizes the clinical relevance of inflammation across the ASCVD continuum. hs-CRP remains useful for risk enhancement in selected primary prevention settings and for identifying residual inflammatory risk in secondary preventionSecondary prevention is treating someone who has already had a heart attack, stroke, or stent, to stop the next one.. Low-dose colchicine has emerged as a practical anti-inflammatory option in selected patients with established ASCVD, and ongoing work on IL-6 pathway modulation and Lp(a)-lowering strategies may further refine treatment.[20,27,30-32,35]

Unresolved Scientific Debates: Defining the Disease

Despite broad convergence, semantic debate persists over whether atherosclerosis is fundamentally lipid driven, inflammatory, or lipid-induced inflammatory. The lipid-centric view is correct in one crucial sense: without ApoB-containing lipoproteins, typical atherosclerosis does not arise. Human genetics, pathology, and lipid-lowering interventions all strongly support this point.[2-5,15,16,23]

Yet a purely lipid-centric model does not fully explain why some patients with excellent lipid control continue to experience plaque rupturePlaque rupture is when the protective cap over a plaque tears open, spilling its contents into the bloodstream. and recurrent events. Conversely, the inflammation-centric view correctly emphasizes that immune mechanisms dominate plaque destabilization, cap degradation, and rupture, but inflammation in a lipid-poor environment does not produce the classic cholesterol-rich atheromaAtheroma is another word for the fatty deposit inside an artery wall — essentially a synonym for plaque, used more often in research writing.. The most accurate synthesis is therefore that atherosclerosis is a lipid-induced inflammatory disease: initiated by ApoB retention, then amplified and rendered clinically dangerous by maladaptive innate and adaptive immune responses to retained lipid.[1-3,10-14,21,22,27,29-35]

Conclusion

The pathophysiology of ASCVD requires convergence of 2 closely linked biological axes. Disease begins with influx and subendothelial retention of ApoB-containing lipoproteins within the arterial wall. This establishes the initiating lesion. Progression from a clinically silent fatty streak to a vulnerable, necrotic, rupture-prone plaque depends on inflammatory amplification driven by modified lipids, foam-cell biology, cholesterol crystals, NLRP3 inflammasome activation, and cytokine signaling through IL-1β and IL-6. hs-CRP emerges from this cascade as an informative systemic marker rather than the primary causal agent.[2-5,10-14,17,18,21]

Landmark trials over the past 2 decades have shown that treating the ApoB driver through statins and PCSK9 inhibition and treating the inflammatory amplifier through IL-1β inhibition or colchicine can provide independent and complementary benefit. To reduce residual cardiovascular riskThe continuing probability of major cardiovascular events that remains even after recognized risk factors such as LDL cholesterol and blood pressure have been brought under control, attributable to persistent calcification, arterial stiffness, low-grade inflammation, and incomplete plaque stabilization. meaningfully, contemporary practice must move beyond cholesterol mass alone and assess both atherogenic particle burden and residual inflammatory activity. That dual-risk framework is the clearest practical implication of modern atherosclerosis research.[4,6-9,19,20,27,29-35]

References

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-874. doi:10.1038/nature01323
2. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications.
3. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis.
4. De Oliveira-Gomes D, Joshi PH, Peterson ED, Rohatgi A, Khera A, Navar AM. Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice. Circulation. 2024;150(1):62-79. doi:10.1161/CIRCULATIONAHA.124.068885
5. Borén J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016;27(5):473-483. doi:10.1097/MOL.0000000000000330
6. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914
7. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. doi:10.1056/NEJMoa0807646
8. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664
9. Pradhan AD, Aday AW, Rose LM, Ridker PM. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy. Circulation. 2018;138(2):141-149. doi:10.1161/CIRCULATIONAHA.118.034645
10. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357-1361. doi:10.1038/nature08938
11. Grebe A, Latz E. Cholesterol crystals and inflammation. Curr Rheumatol Rep. 2013;15(3):313. doi:10.1007/s11926-012-0313-z
12. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129-2138. doi:10.1016/j.jacc.2009.09.009
13. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15(2):104-116. doi:10.1038/nri3793
14. Grebe A, Hoss F, Latz E. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. Circ Res. 2018;122(12):1722-1740. doi:10.1161/CIRCRESAHA.118.311362
15. Tsimikas S, Stroes ESG. The dedicated “Lp(a) clinic”: A concept whose time has arrived?. Atherosclerosis. 2020;300:1-9. doi:10.1016/j.atherosclerosis.2020.03.003
16. Ference BA, Kastelein JJP, Ray KK, et al. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA. 2019;321(4):364-373. doi:10.1001/jama.2018.20045
17. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359(18):1897-1908. doi:10.1056/NEJMoa0707402
18. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow DI, Holmes MV, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214-1224. doi:10.1016/S0140-6736(12)60110-X
19. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-4378. doi:10.1093/eurheartj/ehaf190
20. Patel SB, Wyne KL, Afreen S, et al. American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia. Endocr Pract. 2025;31(2):236-262. doi:10.1016/j.eprac.2024.09.016
21. Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res. 2016;118(1):145-156. doi:10.1161/CIRCRESAHA.115.306656
22. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3):204-212. doi:10.1038/ni.2001
23. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287-1295. doi:10.1001/jamacardio.2019.3780
24. Aday AW, Ridker PM. Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. Front Cardiovasc Med. 2019;6:16. Published 2019 Feb 28. doi:10.3389/fcvm.2019.00016
25. Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014;129(5):553-561. doi:10.1161/CIRCULATIONAHA.113.005873
26. Arsenault BJ, Després JP, Stroes ES, et al. Lipid assessment, metabolic syndrome and coronary heart disease risk. Eur J Clin Invest. 2010;40(12):1081-1093. doi:10.1111/j.1365-2362.2010.02357.x
27. Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. Published online September 29, 2025. doi:10.1016/j.jacc.2025.08.047
28. Sniderman AD, Dufresne L, Pencina KM, Bilgic S, Thanassoulis G, Pencina MJ. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. Eur Heart J. 2024;45(27):2410-2418. doi:10.1093/eurheartj/ehae258
29. Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319-328. doi:10.1016/S0140-6736(17)32814-3
30. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838-1847. doi:10.1056/NEJMoa2021372
31. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-410. doi:10.1016/j.jacc.2012.10.027
32. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497-2505. doi:10.1056/NEJMoa1912388
33. O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019;139(12):1483-1492. doi:10.1161/CIRCULATIONAHA.118.037184
34. Ference BA, Kastelein JJP, Ginsberg HN, et al. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. JAMA. 2017;318(10):947-956. doi:10.1001/jama.2017.11467
35. Du Z, Li F, Jiang L, et al. Metabolic systems approaches update molecular insights of clinical phenotypes and cardiovascular risk in patients with homozygous familial hypercholesterolemia. BMC Med. 2023;21(1):275. Published 2023 Jul 27. doi:10.1186/s12916-023-02967-8